Shanghai Pharmaceuticals' (SHA:601607, HKG:2607) unit, Shanghai Shangyao No. 1 Biochemical & Pharmaceutical, received drug registration certificates from China's National Medical Products Administration for clevidipine injectable emulsion, according to a Shanghai bourse filing over the weekend.
The Chinese pharmaceutical company's Shanghai shares rose 1% during Monday's morning trade.
The drug is used to treat hypertension in patients for whom oral administration is unsuitable or for whom oral drug therapy is expected to be ineffective.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments